Abortion Pill Maker Races to Supreme Court After Fifth Circuit Blocks Mail Distribution

Clear Facts

• A three-judge panel of the Fifth Circuit Court of Appeals temporarily blocked a Biden-era policy allowing mail-order distribution of the abortion pill mifepristone on Friday
• Pharmaceutical company Danco immediately filed an emergency request with the Supreme Court on Saturday seeking to halt the lower court’s ruling
• The Fifth Circuit decision would require in-person physician visits before the abortion pill can be dispensed, reversing years of expanded access policies

The Supreme Court faces another emergency petition involving abortion medication after a federal appeals court moved to restrict mail-order access to mifepristone. The pharmaceutical manufacturer behind the controversial drug is asking the nation’s highest court to intervene.

Danco Laboratories filed the emergency application with the Supreme Court on Saturday, just one day after the Fifth Circuit Court of Appeals issued its decision blocking the Biden administration’s policy that had allowed women to receive the chemical abortion pill through the mail without an in-person doctor visit. The lower court’s ruling would reinstate requirements for face-to-face medical consultations before the drug can be obtained.

The Fifth Circuit’s three-judge panel found sufficient grounds to temporarily halt the mail-order policy while the underlying legal challenge proceeds through the courts. The decision represents a significant legal setback for abortion advocates who have championed expanded access to medication abortion, particularly in states with protective life laws.

Conservative legal experts have long questioned whether the Food and Drug Administration properly evaluated safety concerns when it approved remote prescribing and mail delivery of mifepristone. The drug is used in combination with misoprostol to terminate pregnancies in the early stages.

The Biden administration had dramatically expanded access to chemical abortion pills during the COVID-19 pandemic, eliminating the in-person dispensing requirement that had been in place for years. Pro-life advocates argued this change prioritized ideology over women’s health and safety, removing important medical safeguards.

This emergency Supreme Court filing comes as the legal landscape surrounding abortion continues to evolve following the Court’s historic Dobbs decision in 2022, which returned abortion policy to elected state legislators. Multiple states have since enacted laws protecting unborn life, while others have moved to expand abortion access.

The pharmaceutical company’s petition asks the justices to stay the Fifth Circuit’s order while the case continues in lower courts. The Supreme Court could act on the request within days, potentially restoring mail-order access or allowing the restrictions to remain in effect during litigation.

Medical professionals who support life-affirming alternatives to abortion have raised concerns about complications from unsupervised chemical abortions, including incomplete procedures requiring surgical intervention and the emotional trauma women often experience without proper counseling and support.

The case highlights the ongoing tension between federal drug approval processes and states’ authority to regulate medical practice and protect life within their borders. Legal observers expect the Supreme Court will need to provide clarity on these jurisdictional questions regardless of how it rules on the emergency application.

Let us know what you think, please share your thoughts in the comments below.